Advances in Frontline Management of Peripheral T-cell Lymphoma

Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):368-378. doi: 10.1016/j.clml.2021.01.012. Epub 2021 Jan 22.

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphomas that are frequently associated with a poor prognosis. For many decades, the standard-of-care has been CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)-based therapy, but it is well-recognized that survival outcomes are unsatisfactory, especially when compared with B-cell lymphomas. Major recent advances in cancer diagnosis and management have the potential to significantly improve PTCL outcomes. These include: (1) improved diagnostic techniques that incorporate molecular genetic data to further refine diagnosis and subtyping; (2) the development of novel agents; and (3) improved monitoring modalities, such as 18F-fluorodeoxyglucose positron emission tomography-computed tomography scans and circulating tumor DNA. In this review, we aim to explore these 3 advances in the context of frontline management of PTCL.

Keywords: Disease monitoring; Hematopoietic stem cell transplantation; Molecular diagnostics; Novel agents; Radiotherapy.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Clinical Decision-Making
  • Clinical Trials as Topic
  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / methods
  • Diagnosis, Differential
  • Diagnostic Imaging / methods
  • Disease Management
  • Humans
  • Lymphoma, T-Cell, Peripheral / diagnosis
  • Lymphoma, T-Cell, Peripheral / etiology
  • Lymphoma, T-Cell, Peripheral / mortality
  • Lymphoma, T-Cell, Peripheral / therapy*
  • Molecular Diagnostic Techniques
  • Monitoring, Physiologic
  • Population Surveillance
  • Prognosis
  • Treatment Outcome

Substances

  • Biomarkers, Tumor